LP
TVGNW icon

LMR Partners’s Tevogen Bio Warrant TVGNW Stock Holding History

LMR Partners’s Portfolio TVGNW Stock Details TVGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200,000
Closed -$2.58K – 1661
2024
Q3 		$2.58K Buy
+200,000
New +$3.94K ﹤0.01% 1199

Other funds holding TVGNW

FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

LMR Partners's TVGNW Position: Q1 2026 in Review

LMR Partners held its Tevogen Bio Warrant (TVGNW) position steady in Q1 2026 at 200,000 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

LMR Partners first reported a position in TVGNW in Q4 2022 and has held it in 13 quarters since. The position peaked at $2.16M in Q1 2023. 33 funds tracked by Wall St. Rank hold TVGNW as of Q1 2026.

  • LMR Partners held 200,000 shares of Tevogen Bio Warrant worth $6.78K as of Q1 2026.
  • LMR Partners left its Tevogen Bio Warrant share count unchanged in Q1 2026.
  • Tevogen Bio Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1381 holding.
  • LMR Partners first reported a position in Tevogen Bio Warrant in Q4 2022 and has held it in 13 quarters since.
  • LMR Partners's Tevogen Bio Warrant position peaked at $2.16M in Q1 2023.
  • 33 funds tracked by Wall St. Rank held Tevogen Bio Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.